Mesentech was founded by Dr. Robert Young,  who led teams that discovered SingulAir, Vioxx, Arcoxia, ondanacatib, among others while leading medicinal chemistry at Merck. Mesentech lead compound is MES1022, a bone-targeted prodrug that has the potential to reverse bone-loss caused by diseases such as Duchenne muscular dystrophy and osteoporosis. Mesentech is also leveraging bi-specific drug conjugate technology to develop new drugs for hematological and gastrointestinal diseases.